Business Context and Reporting Period
The filing is MultiPlan Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2021. Although the request identifies Claritev Corp, the provided filing names MultiPlan Corporation, formerly Churchill Capital Corp III, as the registrant. MultiPlan provides data analytics, network-based, payment integrity, and revenue integrity solutions to U.S. healthcare payors.
The October 2020 business combination was accounted for as a reverse recapitalization, so the historical comparative period reflects the predecessor MultiPlan business. The company operated as a single U.S. reportable segment and reported access to more than 1.2 million healthcare providers.
Key Financial Metrics
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue | $254.9 million | $252.0 million | Up 1.1% |
| Operating income | $82.3 million | $87.6 million | Down 6.1% |
| Operating margin | 32.3% | 34.8% | Down approximately 250 basis points |
| Net income (loss) | $45.9 million | $(2.6) million | Improved by $48.5 million |
| Basic and diluted EPS | $0.07 | $(0.01) | Improved |
| Adjusted EBITDA | $191.1 million | $195.9 million | Down 2.5% |
| Adjusted EBITDA margin | 75.0% | 77.8% | Down approximately 280 basis points |
| Cash flow from operations | $170.9 million | $147.4 million | Up 15.9% |
Revenue consisted of $69.4 million from Network Services, $157.2 million from Analytics-Based Services, and $28.3 million from Payment and Revenue Integrity Services. Medical charges processed increased to $28.9 billion from $25.9 billion, while potential medical cost savings remained approximately $4.9 billion.
At March 31, 2021, cash and cash equivalents were $135.0 million, compared with $126.8 million at December 31, 2020. Total current assets were $211.7 million and total current liabilities were $216.1 million. The company reported $450.0 million of availability under its revolving credit facility and $1.8 million of outstanding letters of credit.
Long-term debt, net, was $4.879 billion, including a $2.341 billion Term Loan G, $1.300 billion of 5.750% senior notes, and $1.300 billion of senior convertible PIK notes. The annualized weighted-average cash interest rate was approximately 4.9%. The company reported compliance with its debt covenants and a consolidated first-lien debt-to-consolidated EBITDA ratio of 3.15 times.
Material Changes Versus the Prior Comparable Period
- Revenue increased modestly because of $7.2 million of acquired revenue from HST and DHP and growth in Analytics-Based and Payment and Revenue Integrity Services. Network Services revenue declined 5.7%, partly because customers shifted claims to analytics products and because COVID-19 reduced healthcare utilization.
- Costs of services declined 11.1%, primarily because prior-period stock-based compensation was substantially higher. Excluding stock-based compensation, costs of services increased 1.2%.
- General and administrative expense increased 47.4% to $32.0 million, driven by $5.2 million of transaction-related costs, higher insurance costs associated with being public, and increased professional fees.
- Operating income declined despite higher revenue because of increased general and administrative, depreciation, and amortization expenses.
- Interest expense declined 30.0% to $63.7 million following debt refinancing, repayment of $369.0 million of Term Loan G, redemption of the 8.5% Senior PIK Notes, and replacement of 7.125% notes with 5.750% notes.
- Net income benefited from a $40.4 million non-cash gain from the decrease in the fair value of Private Placement Warrants and unvested founder shares. This gain was primarily attributable to a decline in the company’s stock price.
- Operating cash flow increased, but investing cash outflows rose substantially to $162.4 million, including $149.9 million for the DHP acquisition and $18.1 million for property and equipment and capitalized software.
- The adoption of ASU 2020-06 increased long-term debt by $297.9 million, reduced additional paid-in capital by $233.9 million, and increased beginning retained earnings by $6.0 million.
Guidance, Outlook, Commentary, Risks, and Unusual Items
Management did not provide specific financial guidance in the filing. Management stated that internally generated cash and revolver capacity should be sufficient to meet working capital, capital expenditure, and other cash requirements for at least the next twelve months, while noting that future liquidity depends on operating performance, economic conditions, lender capacity, and access to additional financing.
- COVID-19 continued to negatively affect results through lower claim volumes and changes in medical claims mix. Excluding HST and DHP, management reported an approximately 1.7% net revenue decline for the first quarter compared with the prior year. The ultimate effects remain uncertain.
- The DHP acquisition closed February 26, 2021 for $152.0 million of cash consideration and generated $108.4 million of goodwill. Its first-quarter revenue and earnings contribution was not material.
- The company had two material weaknesses in internal control over financial reporting as of March 31, 2021: insufficient accounting resources and insufficient formal accounting policies, procedures, and controls for public-company reporting, including debt and equity accounting. Management stated that remediation efforts were ongoing and the weaknesses were not remediated.
- Putative litigation relating to the Transactions includes consolidated Delaware stockholder litigation alleging fiduciary-duty violations and a securities class action filed in April 2021. The company stated that it could not reasonably estimate a potential loss and had not recorded a contingency accrual.
- Private Placement Warrants and unvested founder shares are classified as derivative liabilities and remeasured through earnings. Their fair value was $66.2 million at March 31, 2021, creating potential for material quarterly earnings volatility.
- Debt agreements contain restrictions on additional debt, distributions, asset transfers, liens, investments, affiliate transactions, and certain corporate transactions. LIBOR transition could affect debt agreements after 2023.
- Two customers individually accounted for 35% and 20% of revenue for 2020, creating customer concentration risk.
Important Facts for Investors to Verify
- Confirm the correct registrant and company identity, since the request refers to Claritev Corp but the supplied filing is for MultiPlan Corporation.
- Assess recurring operating performance separately from the $40.4 million non-cash warrant and founder-share valuation gain, acquisition-related costs, and other adjustments.
- Review debt maturities, conversion terms, cash-versus-PIK interest elections, covenant headroom, and exposure to LIBOR transition.
- Evaluate whether COVID-19-related utilization changes and customer migration between Network Services and Analytics-Based Services are temporary or structural.
- Monitor integration results and purchase-accounting updates for the DHP acquisition and the contribution from HST.
- Track remediation of the two material weaknesses in internal control over financial reporting.
- Review developments and potential financial exposure from the Delaware stockholder litigation and the Paradis securities action.
- Consider dilution from 58.5 million outstanding warrants, 100 million shares issuable upon conversion of the Senior Convertible PIK Notes, unvested founder shares, and equity compensation awards.